CRH (CRH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Proxy statement filed under Schedule 14A in accordance with Section 14(a) of the Securities Exchange Act of 1934.
Filing is definitive and no fee was required for submission.
Voting matters and shareholder proposals
Proxy statement relates to matters requiring shareholder voting as per SEC regulations.
Shareholder rights and capital structure
Filing confirms the registrant's compliance with SEC proxy solicitation rules.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026